Literature DB >> 17435569

Rapid relief of severe major depressive disorder by use of preoperative ketamine and electroconvulsive therapy.

Harold W Goforth1, Tracey Holsinger.   

Abstract

Major depressive disorder is a difficult-to-treat and recurrent debilitating disorder. All approved somatic treatments for major depression to date require a significant time lapse before demonstrating an antidepressant effect. However, emerging evidence indicates a potential role for the use of ketamine to rapidly relieve symptoms of major depression. We present a case of severe, recurrent major depressive disorder that demonstrated marked improvement within 8 hours of receiving a preoperative dose of ketamine and 1 treatment of electroconvulsive therapy with bitemporal electrode placement. This case is supportive of a role of ketamine in relieving symptoms of major depressive disorder rapidly and safely.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17435569     DOI: 10.1097/01.yct.0000263257.44539.23

Source DB:  PubMed          Journal:  J ECT        ISSN: 1095-0680            Impact factor:   3.635


  19 in total

Review 1.  Ketamine for depression: where do we go from here?

Authors:  Marije Aan Het Rot; Carlos A Zarate; Dennis S Charney; Sanjay J Mathew
Journal:  Biol Psychiatry       Date:  2012-06-16       Impact factor: 13.382

2.  Lack of persistent effects of ketamine in rodent models of depression.

Authors:  Piotr Popik; Tomasz Kos; Magdalena Sowa-Kućma; Gabriel Nowak
Journal:  Psychopharmacology (Berl)       Date:  2008-05-07       Impact factor: 4.530

3.  Post-electroconvulsive therapy recovery and reorientation time with methohexital and ketamine: a randomized, longitudinal, crossover design trial.

Authors:  Tony Yen; Mohamad Khafaja; Nicholas Lam; James Crumbacher; Ronald Schrader; John Rask; Mary Billstrand; Jacob Rothfork; Christopher C Abbott
Journal:  J ECT       Date:  2015-03       Impact factor: 3.635

4.  S -ketamine compared to etomidate during electroconvulsive therapy in major depression.

Authors:  Maxim Zavorotnyy; Ina Kluge; Kathrin Ahrens; Thomas Wohltmann; Benjamin Köhnlein; Patricia Dietsche; Udo Dannlowski; Tilo Kircher; Carsten Konrad
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-04-19       Impact factor: 5.270

5.  Ketofol in electroconvulsive therapy anesthesia: two stones for one bird.

Authors:  Saban Yalcin; Harun Aydoğan; Salih Selek; Ahmet Kucuk; Hasan Husnu Yuce; Fatih Karababa; Tekin Bilgiç
Journal:  J Anesth       Date:  2012-05-24       Impact factor: 2.078

6.  Use of ketamine in acute cases of suicidality.

Authors:  Jae Lee; Puneet Narang; Manasa Enja; Steven Lippmann
Journal:  Innov Clin Neurosci       Date:  2015 Jan-Feb

7.  Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting.

Authors:  Chadi G Abdallah; Madonna Fasula; Ben Kelmendi; Gerard Sanacora; Robert Ostroff
Journal:  J ECT       Date:  2012-09       Impact factor: 3.635

Review 8.  Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Lobna A Ibrahim; Nancy Diaz-Granados; Carlos A Zarate
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

9.  Innovative approaches to treatment - refractory depression: The ketamine story.

Authors:  T S Sathyanarayana Rao; Chittaranjan Andrade
Journal:  Indian J Psychiatry       Date:  2010-04       Impact factor: 1.759

Review 10.  Ketamine and the next generation of antidepressants with a rapid onset of action.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Nancy Diazgranados; Carlos A Zarate
Journal:  Pharmacol Ther       Date:  2009-05-03       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.